Oragenics
OGEN

$0.4914

1.74%

Market Cap: $4.26M

About: Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Employees: 5

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

15% more funds holding

Funds holding: 13 [Q1] → 15 (+2) [Q2]

1.84% less ownership

Funds ownership: 4.17% [Q1] → 2.33% (-1.84%) [Q2]

50% less capital invested

Capital invested by funds: $269K [Q1] → $136K (-$134K) [Q2]

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for OGEN.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about OGEN published over the past 30 days

Oragenics, Inc. Announces Closing of Public Offering

SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced offering of 3,078,378 shares of its common stock and pre-funded warrants to purchase up to 5,028,206 shares of common stock at an offering price of $0.55 per share and $0.549 per pre-funded warrant. Immediately after the closing of the offering, the Company has 8,659,071 shares of common stock outstanding and pre-funded warrants to acquire up to 5,028,206 shares of common stock outstanding. The exercise price of each pre-funded warrant is $0.001.

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 8,106,584 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.55 per share (or $0.549 per pre-funded warrant in lieu thereof).

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for concussion; drug, ONP-002, could be first of its kind to treat concussion SARASOTA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced recent and key 2024 business progress. The Company continues to execute its business strategy to develop and advance its lead candidate, ONP-002, for the treatment of concussion. Phase 2 human trials are being planned with anticipation of starting in the fourth quarter of this year.

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

• ONP-002 stability eliminates need for cumbersome cold storage • No FDA-approved pharmaceutical treatment available for concussion

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced its lead candidate for treating concussion, ONP-002, successfully completed a study that indicates it does not cause DNA damage and genotoxicity in an animal model.

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Closing of Public Offering

SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share. The closing of the public offering is expected to occur on or about June 26, 2024, subject to the satisfaction of customary closing conditions.

Oragenics, Inc. Announces Pricing of Public Offering

See News Rankings